Price
Target price
€0.27
€0.27
-
-
-
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Recce Pharmaceuticals Ltd. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
S********** s********
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
News
U.S. Department of Defense Grants US$2 million for RECCE® 327 Gel
Highlights:
- US Department of Defense grants funding of US$2 million (approximately A$3 million)
- Funding to accelerate development of RECCE® 327 Gel (R327G) for
Positive Efficacy Data from Murdoch Children’s Research Institute in Study against WHO Priority Pathogen Acinetobacter baumannii
Highlights:
- RECCE® 327 (R327) demonstrates significant bactericidal activity against ‘superbug’ Acinetobacter baumannii (A. baumannii) in adult human epidermal ‘skin’ cells:
Recce Pharmaceuticals Reports Positive Data From Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial of RECCE® 327
Highlights:
- Phase I/II rapid infusion clinical trial demonstrates efficacy on bacterial growth in dosed participants injected with RECCE® 327 (R327) at the highest tested dose of